Novartis, Astra win EU drug okays; Pfizer loses out

<p>LONDON (Reuters) – <span>Novartis</span> and <span>AstraZeneca</span> won recommendations for critical new drugs from European regulators on Friday, while opposition <span>Pfizer</span> mislaid out.</p>
<p> <span>The European Medicines Agency</span> pronounced a <span>Committee for Medicinal Products for Human Use</span> (CHMP) had permitted Novartis’s Afinitor for treating breast cancer in further to other growth types. It also okayed AstraZeneca’s new antibiotic Zinforo.</p>
<p> AstraZeneca cumulative rights to a antibiotic, also famous as ceftaroline, outward North America and Japan from <span>Forest Laboratories</span> in 2009.</p>
<p> Pfizer, however, unsuccessful to secure subsidy for Elelyso, a new diagnosis for Gaucher illness that was authorized in a United States in May.</p>
<p> The London-based gr...